Core Viewpoint - BiomX Inc. is set to host a conference call on May 15, 2025, to discuss its first quarter 2025 financial results and provide updates on its business and programs [1]. Company Overview - BiomX is a clinical-stage company focused on developing natural and engineered phage therapies aimed at targeting and eliminating specific pathogenic bacteria [3]. - The company utilizes its proprietary BOLT ("BacteriOphage Lead to Treatment") platform to customize phage compositions against validated bacterial targets [3].